ESMO Congress | Conference

Study Demonstrates Improved Responses With Molecularly-Guided Therapy in mRCC

September 21st 2020

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

Cemiplimab Demonstrates Frontline Potential in Advanced PD-L1+ NSCLC

September 21st 2020

Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21st 2020

The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.

Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma

September 21st 2020

First-line treatment with the combination of nivolumab and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma versus chemotherapy alone.

Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer

September 21st 2020

Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.

Durvalumab/Tremelimumab Shows Modest Activity in Advanced NETs With GEP and Lung Origins

September 21st 2020

The addition of durvalumab to tremelimumab showed modest activity in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins.

Pembrolizumab Prolongs PFS in Rare Sarcoma Subtypes

September 21st 2020

Pembrolizumab monotherapy prolonged progression-free survival in selected rare sarcoma subtypes, supporting the immune checkpoint inhibitor’s ability to improve outcomes across histotypes.

Cabozantinib Combo Induces Clinical Activity in Advanced ccRCC

September 21st 2020

Treatment with cabozantinib in combination with atezolizumab demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma.

Weekly Dose-Dense Chemotherapy Not Superior to Standard of Care in Epithelial Ovarian Cancer

September 21st 2020

Weekly dose-dense chemotherapy is not superior to standard 3 weekly chemotherapy for patients with epithelial ovarian cancer when it comes to progression-free survival and overall survival, though the regimen is safe and effective.

Significant Improvement in PFS Seen With Palbociclib/Fulvestrant in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer

September 21st 2020

Frontline fulvestrant in combination with palbociclib demonstrated an improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone in patients with endocrine-sensitive hormone receptor-positive, HER2-negative metastatic breast cancer, which met the primary end point of the phase 2 FLIPPER trial.

Osimertinib Improves CNS Disease-Free Survival in Early EGFRm NSCLC

September 21st 2020

Osimertinib reduced the risk for central nervous system death or progression by 82% in patients with early-stage EGFR mutated non–small cell lung cancer following complete tumor resection.

Pembrolizumab/Chemo Combo Represents New Frontline Standard in Advanced Esophageal Cancer

September 21st 2020

Frontline pembrolizumab plus chemotherapy significantly improved overall survival, progression-free survival, and objective response rates compared with chemotherapy alone in patients with locally advanced unresectable or metastatic esophageal cancer.

Novel BiTE Immuno-Oncology Therapy Appears Safe with Preliminary Efficacy in mCRPC

September 21st 2020

Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

Tucatinib Regimen Maintains Health-Related QoL in HER2+ Metastatic Breast Cancer

September 21st 2020

The addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer with and without brain metastases resulted in statistically significant and clinically meaningful improvements in progression-free and overall survival.

Lenvatinib/Pembrolizumab Combo Shows Antitumor Activity in Previously Treated Advanced Solid Tumors

September 20th 2020

Lenvatinib plus pembrolizumab showed early antitumor activity and tolerability in previously treated patients with advanced solid tumors.

Frontline Ipatasertib/Abiraterone Regimen Shows Superior Radiographic PFS in PTEN-Loss mCRPC

September 20th 2020

Ipatasertib combined with abiraterone acetate plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity compared with placebo plus abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer with PTEN loss.

Long-Term Follow-Up Shows Encouraging OS With Enfortumab Vedotin in Urothelial Carcinoma

September 20th 2020

Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.

BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models

September 20th 2020

BLU-945, an investigational precision therapy, elicited robust antitumor activity in multiple preclinical models of triple-mutated EGFR-positive non–small cell lung cancer .

Surufatinib Improves PFS in Advanced Pancreatic NETs

September 20th 2020

The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors.

Dr. Lwin on the Results of the LEAP-005 Trial in Advanced Solid Tumors

September 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the results of the LEAP-005 trial in advanced solid tumors.